

199at09.us
8602*36

REMARKS

Claims 4, 5, 12, 13, 14 and 15 have been amended to refer to only one preceding claim. New claims 16-23 have been added. Each of the dependent claims, as amended, now depends on only one preceding claim. Therefore, no additional fee is required for multiple dependency.

Prompt and favorable action concerning claims 1-23 is solicited.

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ LLP

By: 

William E. McShane
Reg. No. 32,707
P. O. Box 2207
Wilmington, DE 19899
(302) 888-6248
Attorney for Applicants

WEM:bjm
Enclosure: Appendix A
::ODMA\HODMA\CB;175363;1

Appendix A
Underline/Bracket Version of Amended Claims

4. (Amended) A vector comprising a sequence as claimed in claim 1 [or a recombinant DNA molecule as claimed in either of claims 2 and 3].
5. (Amended) A host organism, except a human, comprising a [recombinant DNA molecule as claimed in either of claims 2 and 3 or a] vector as claimed in claim 4.
12. (Amended) A pharmaceutical comprising a nucleic acid as claimed in [any of claims 1 to 3 and/or a spliceosomal protein as claimed in either of claims 8 and 9] claim 1 and, where appropriate, pharmaceutically acceptable additives and/or excipients.
13. (Amended) A process for producing a pharmaceutical for the treatment of cancer, autoimmune diseases, in particular Grave's disease, spinal muscular atrophy, β '-thalassemia, cancers related to the c-erb oncogene, hepatitis C infection, herpes simplex virus infection, systemic lupus erythematosus, Hermansky-Pudlak syndrome, which comprises formulating a nucleic acid as claimed in [any of claims 1 to 3 and/or a spliceosomal protein as claimed in either of claims 8 and 9] claim 1 together with a pharmaceutically acceptable additive and/or excipient.

14. (Amended) A diagnostic agent comprising nucleic acid as claimed in [any of claims 1 to 3 and/or a spliceosomal protein as claimed in either of claims 8 and 9] claim 1 and, where appropriate, pharmaceutically acceptable additives and/or excipients.
15. (Amended) A process for producing a diagnostic agent for diagnosis of Grave's disease, spinal muscular atrophy, β' -thalassemia, cancers related to the c-erb oncogene, hepatitis C infection, herpes simplex virus infection, systemic lupus erythematosus, Hermansky-Pudlak syndrome, which comprises adding a pharmaceutically acceptable carrier to a nucleic acid as claimed in [any of claims 1 to 3 and/or a spliceosomal protein as claimed in either of claims 8 and 9] claim 1.